<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Lumis International</title>
	<atom:link href="https://lumisinternational.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://lumisinternational.com/</link>
	<description>We accelerate your clinical development</description>
	<lastBuildDate>Fri, 03 Jul 2026 13:15:04 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://lumisinternational.com/wp-content/uploads/2020/07/cropped-Favicon-Lumis-1-32x32.png</url>
	<title>Lumis International</title>
	<link>https://lumisinternational.com/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Integrating Service Provider Management and Risk‑Based Quality Systems under ICH E6(R3)</title>
		<link>https://lumisinternational.com/integrating-service-provider-management-and-risk-based-quality-systems-under-ich-e6r3/</link>
		
		<dc:creator><![CDATA[Frauke Bach]]></dc:creator>
		<pubDate>Wed, 14 Jan 2026 14:56:13 +0000</pubDate>
				<category><![CDATA[Clinical trial management & oversight services]]></category>
		<guid isPermaLink="false">https://lumisinternational.com/?p=47039</guid>

					<description><![CDATA[<p>Delegating with oversight empowers responsible outcomes. By integrating rigorous service provider management with a cross‑functional, risk‑based quality management system, sponsors can fulfil their oversight duties in alignment with ICH E6(R3). This article outlines practical “to‑dos” for ensuring compliant trial conduct, participant safety, and data integrity.</p>
<p>The post <a href="https://lumisinternational.com/integrating-service-provider-management-and-risk-based-quality-systems-under-ich-e6r3/">Integrating Service Provider Management and Risk‑Based Quality Systems under ICH E6(R3)</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-full content_image"><img fetchpriority="high" decoding="async" width="950" height="625" src="https://lumisinternational.com/wp-content/uploads/2026/01/compliant-clinical-trials-ich-e6r3.jpg" alt="A graphic showing a hand with a diagram above it of a stylised globe with groups of people overlaid on it" class="wp-image-47038" srcset="https://lumisinternational.com/wp-content/uploads/2026/01/compliant-clinical-trials-ich-e6r3.jpg 950w, https://lumisinternational.com/wp-content/uploads/2026/01/compliant-clinical-trials-ich-e6r3-300x197.jpg 300w, https://lumisinternational.com/wp-content/uploads/2026/01/compliant-clinical-trials-ich-e6r3-768x505.jpg 768w" sizes="(max-width: 950px) 100vw, 950px" /></figure>



<p class="wp-block-paragraph">The globalization and increasing complexity of clinical trials have led sponsors to engage multiple specialized service providers—ranging from central laboratories and data managers to imaging and safety vendors—to execute delegated trial activities. Under ICH E6(R3) Good Clinical Practice (GCP), however, delegation does not relieve the sponsor of ultimate responsibility. To fulfil regulatory and ethical obligations, sponsors must implement a robust oversight framework that links service provider management with a cross‑functional, risk‑based quality system focused on Critical to Quality (CtQ) factors. This article outlines practical “to‑dos” for ensuring compliant trial conduct, participant safety, and data integrity.</p>



<h2 class="wp-block-heading">1. Defining and Documenting Roles</h2>



<p class="wp-block-paragraph">First and foremost, ICH E6(R3) Section 10 mandates that all trial roles and responsibilities be clearly defined and documented. Whether transferring activities to a service provider or delegating functions to an investigator, sponsors retain accountability. Sponsors must ensure comprehensive agreements that:</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Enumerate delegated tasks, deliverables, and timelines;</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Define responsibilities; From my point of view, take the time to meet the teams and make sure to align your expectations. There often are different expectations / interpretations of the same task and responsibility that have the potential to inhibit the flow when two parties are involved sequentially. This is especially important when you outsource partially.</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Detail the GCP and regulatory standards to be met;</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Specify the sponsor’s rights to monitor, audit, and access source data at service provider sites; Take current developments into account and discuss for example the rights to fully access electronic source data.</p>



<p class="wp-block-paragraph">These agreements form the foundation for subsequent oversight and ensure transparency in the sponsor–provider relationship.</p>



<p class="wp-block-paragraph">Reference: Section 10, ICH E6(R3)</p>



<h2 class="wp-block-heading">2. Service Provider Selection and Qualification</h2>



<p class="wp-block-paragraph">A cornerstone of effective oversight is selecting competent service providers. Sponsors must perform a structured qualification process—reviewing SOPs, financial stability, quality metrics, training schedules and regulatory inspection history—to verify that providers can carry out assigned activities.</p>



<p class="wp-block-paragraph">Are the SOPs shared to allow you to check them? Remember this when your vendors work according to their SOPs.</p>



<p class="wp-block-paragraph">Selection teams should include representatives from clinical operations, quality assurance, data management, and pharmacovigilance to ensure a cross‑functional perspective on critical processes. Access to performance metrics, audit reports, and relevant certifications is essential for informed decision‑making, as well as handling of sub-contacted vendor handling.</p>



<p class="wp-block-paragraph">Reference: Sections 3.6.7–3.6.8, ICH E6(R3)</p>



<h2 class="wp-block-heading">3. Establishing Oversight and Monitoring Measures</h2>



<p class="wp-block-paragraph">Once engaged, service providers must be monitored to confirm GCP compliance. My initial focus here is to engage with involved people and teams to create the base for your collaboration: A space of free communication and trust.</p>



<p class="wp-block-paragraph">For example: Talk to your CRAs to make sure your trials “specialties” are understood. This is your option to have your sites strongly guided through your study visits.</p>



<p class="wp-block-paragraph">Key oversight activities include:</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Regular status meetings with documented minutes;</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Periodic performance reviews against agreed KPIs;</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Quality audits tailored to each provider’s risk profile;</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Real‑time tracking of deviations, incidents, and corrective actions.</p>



<p class="wp-block-paragraph">Agreements should grant sponsors the right to audit and inspect—both on‑site and remotely—and to obtain direct access to source records. Sponsors should also ensure that any subcontracting downstream does not dilute oversight and that providers’ internal quality processes are “fit for purpose” within a GCP context.</p>



<p class="wp-block-paragraph">Reference: Sections 3.6.4–3.6.6, 3.6.9–3.6.10, ICH E6(R3)</p>



<h2 class="wp-block-heading">4. Embedding Risk‑Based Quality Management</h2>



<p class="wp-block-paragraph">ICH E6(R3) calls for a proportionate approach to quality driven by CtQ factors—those trial elements that directly impact participant rights, safety, and data reliability. A risk‑based quality management system comprises five integrated steps:</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1. Risk Identification:</p>



<p class="wp-block-paragraph">Map all trial processes—including service provider activities such as data transfers, lab assays, and central imaging analyses—and identify potential hazards that could affect CtQ factors.</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. Risk Evaluation:</p>



<p class="wp-block-paragraph">Assess the likelihood, detectability, and impact of each risk. For instance, errors in randomization systems could have high impact and low detectability, warranting enhanced controls.</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3. Risk Control:</p>



<p class="wp-block-paragraph">Define and implement mitigation measures—such as redundant data checks, prespecified quality tolerance limits, or additional training—scaled to the importance of each risk.</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4. Risk Communication:</p>



<p class="wp-block-paragraph">Disseminate risk assessments and mitigation plans to cross‑functional stakeholders, including service providers, data managers, clinical operations, and safety teams.</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5. Risk Review and Reporting:</p>



<p class="wp-block-paragraph">Continuously monitor emerging data and periodic performance metrics to validate the effectiveness of controls. Document and report any excursions beyond quality limits, along with remedial actions.</p>



<p class="wp-block-paragraph">Important: Keep your risk assessment active and continuous. Risks and risk evaluation may change over the course of your trial.</p>



<p class="wp-block-paragraph">One example of practice: Do not postpone your risk assessment to “the break after submission”. When thoroughly going through your processes and individual study specialties you may find aspects that lead to a protocol amendment.</p>



<p class="wp-block-paragraph">Reference: Sections 3.10 &amp; 3.9, ICH E6(R3)</p>



<h2 class="wp-block-heading">5. Oversight Governance and Decision‑Making</h2>



<p class="wp-block-paragraph">Sponsors must tailor oversight measures to the trial’s complexity and risk profile. A governance structure may include:</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Safety Team Meetings: Medical teams to monitor decision impact on safety and data integrity, and protocol deviations classified as “important”.</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Periodic review of key metrics, CtQ trends. Keep in mind that each phase of your clinical trial may come with different risk factors. &nbsp;</p>



<p class="wp-block-paragraph">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; • Independent Data Monitoring Committees (IDMCs): For trials with significant safety or efficacy endpoints, IDMCs provide unbiased recommendations on trial continuation.&nbsp;&nbsp;&nbsp;</p>



<p class="wp-block-paragraph">All trial decisions—ranging from protocol amendments to urgent safety measures—must be risk‑assessed for their impact on participant welfare and data validity and escalated promptly if issues arise.</p>



<p class="wp-block-paragraph">From my experience, an overview of key decisions and FAQs, continuously updated and made available for your PM, CRAs and Sites adds great value to your portfolio. &nbsp;</p>



<p class="wp-block-paragraph">Reference: Section 3.9, ICH E6(R3)</p>



<h2 class="wp-block-heading">6. Cross‑Functional Collaboration and Continuous Improvement</h2>



<p class="wp-block-paragraph">Effective sponsor oversight demands seamless collaboration across functional silos. Clinical operations drive execution, quality assurance verifies compliance, data management tracks metrics, and pharmacovigilance safeguards safety signals. Regular cross‑functional forums enable proactive identification of systemic issues and continuous refinement of oversight strategies.</p>



<h2 class="wp-block-heading">Conclusion</h2>



<p class="wp-block-paragraph">By integrating rigorous service provider management with a cross‑functional, risk‑based quality management system anchored on Critical to Quality factors, sponsors can fulfil their oversight duties in alignment with ICH E6(R3). That documentation will be expected from regulatory authorities and also enhances trial efficiency, participant protection, and the integrity of data that underpin clinical and regulatory decision‑making: Delegating with oversight empowers responsible outcomes.</p>
<p>The post <a href="https://lumisinternational.com/integrating-service-provider-management-and-risk-based-quality-systems-under-ich-e6r3/">Integrating Service Provider Management and Risk‑Based Quality Systems under ICH E6(R3)</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>2025 Conference Insights: What industry trends may impact your business?</title>
		<link>https://lumisinternational.com/2025-conference-insights-what-industry-trends-may-impact-your-business/</link>
		
		<dc:creator><![CDATA[Heike Schoen]]></dc:creator>
		<pubDate>Mon, 15 Dec 2025 15:40:28 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://lumisinternational.com/?page_id=47007</guid>

					<description><![CDATA[<p>This year Lumis attended 14 conferences – ensuring we are up to date with the latest industry trends and news. Our experts presented at conferences, sharing their experience, insights, and demonstrating their thought leadership.</p>
<p>The post <a href="https://lumisinternational.com/2025-conference-insights-what-industry-trends-may-impact-your-business/">2025 Conference Insights: What industry trends may impact your business?</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-full rounded-corner-image left-image"><img decoding="async" width="950" height="600" src="https://lumisinternational.com/wp-content/uploads/2025/12/lumis-conference-insights-2025.jpg" alt="Photo of Andrés Aguilar from Lumis on stage at the COG Nordic conference 2025" class="wp-image-46998" srcset="https://lumisinternational.com/wp-content/uploads/2025/12/lumis-conference-insights-2025.jpg 950w, https://lumisinternational.com/wp-content/uploads/2025/12/lumis-conference-insights-2025-300x189.jpg 300w, https://lumisinternational.com/wp-content/uploads/2025/12/lumis-conference-insights-2025-768x485.jpg 768w" sizes="(max-width: 950px) 100vw, 950px" /></figure>



<div style="height:2em" aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">This year Lumis attended <strong>14 conferences</strong> – ensuring we are up to date with the latest industry trends and news. Our experts presented at conferences, sharing their experience, insights, and demonstrating their thought leadership.</p>



<p class="wp-block-paragraph">Here is a distilled summary of the most critical takeaways and <strong>what they mean for your company.</strong></p>



<div style="height:1em" aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Executive Summary: Critical Trends to Watch</h2>



<ul class="wp-block-list">
<li><strong>Clinical Trials Outsourcing:</strong> Sponsors are consolidating vendors to simplify trial management, but the rise of separate legal representative outsourcing demands a harmonized approach to contracts and project oversight across all partners.</li>



<li><strong>Medical Device Global Expansion</strong>: Small medtech companies often underestimate the value of CE-marking in global registrations. To avoid reduced market agility from relying heavily on distributors, more companies are seeking independent partners for global registrations.</li>



<li><strong>Artificial Intelligence (AI):</strong> AI is a core theme in biotech and medtech, used in products and drug development (e.g., digital twins). It may also reduce operational costs for greater competitiveness, which could be particularly powerful for Notified Bodies. This innovation, however, comes with distinct regulatory challenges</li>
</ul>



<div style="height:1em" aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Expert Insights on Industry Shifts</h2>



<p class="wp-block-paragraph"><em>“<strong>Biopharma: </strong>There is a growing shift in combining the economic health technology assessments with the regulatory market authorisation applications. This was evident at the Orphan Congress where the Joint Clinical Assessments (JCA) was a major topic, although the scope and capacity of JCA is currently limited.</em> <em>&nbsp;</em> <em>Interestingly, 50% of orphan drug applications are from emerging biotechnology companies which shows the importance of a diverse small-to-medium sized ecosystem for addressing rare diseases.</em> <em>&nbsp;</em> </p>



<p class="wp-block-paragraph"><strong><em>Artificial Intelligence (AI) </em></strong><em>is a key theme in the medical technology industry. It is being applied as a medical technology, which poses regulatory challenges with the MDR/IVDR but also the AI Act. However, it is also being utilised by service providers to streamline regulatory document preparation. A key opportunity for me is if Notified Bodies can utilise AI to reduce their operational costs. This could make Notified Body fees more affordable to small MedTech companies and increase the supply and competitiveness of the market, helping combat the repercussions of the MDR and IVDR.</em> <em>&nbsp;</em> </p>



<p class="wp-block-paragraph"><strong><em>Combination Products: </em></strong><em>20% of market authorisation applications are combination (drug-device) products. Hence, an understanding of Article 117 (MDR) and device classification rules is crucial. The EU’s COMBINE project is helping address the challenges of complying to the MDR/IVDR and Clinical Trials Regulations (CTR) for combined product studies.</em> <strong><em>&nbsp;</em></strong> </p>



<p class="wp-block-paragraph"><strong><em>Funding: </em></strong><em>The last few years have proven challenging for fundraising biotech and medtech start-ups. For example, only 0.2% of proposals to investors are funded. However, there are ways to maximise the chances. Start-ups should carefully select venture capitalists to align with their company’s strategy. Furthermore, there are growing opportunities in big pharma VCs and mergers and acquisitions. Lastly, for early start-ups there are ‘outside the box’ finance options, particularly for medtech, such as the ‘Defence and Security Accelerator’.”</em> <strong><em>&nbsp;</em></strong><br></p>


<div class='author-details'><img src='/wp-content/themes/lumis-child/dist/img/content/Team/liam-spencer.jpg' width='450' height='450' loading='lazy' decoding='async' alt='Liam Spencer'><p><strong>Liam Spencer</strong><br>Head of Regulatory Services</p></div>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<div style="height:2em" aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph"><strong><em>“Clinical trials:</em></strong><em> CROs are increasingly stepping away from handling Legal Representation due to the conflict of interest and the added burden it brings, and sponsors now recognise that regulators and even investors can view it more positively when an independent partner oversees the trial.</em> <em>&nbsp;</em> </p>



<p class="wp-block-paragraph"><strong><em>MedTech: </em></strong><em>There is still a lot of hesitation from small and non-EU manufacturers about entering the EU market, mainly due to the high cost, long timelines, and complexity of CE marking. Quite a few underestimate what it takes, especially for higher-risk classes requiring NB.</em> <em>&nbsp;</em> </p>



<p class="wp-block-paragraph"><strong><em>Global Expansion: </em></strong><em>We met several early-stage MedTech teams who are unsure which markets to prioritise; some chase EU entry before realising it may not be the most strategic first step, while others avoid the topic altogether and overlook the opportunities EU market can bring. Overall, there is a strong need for expert-led planning and independent partners who can help companies navigate these decisions confidently and consciously.”</em> </p>


<div class='author-details'><img src='/wp-content/themes/lumis-child/dist/img/content/Team/stella-vu.jpg' width='450' height='450' loading='lazy' decoding='async' alt='Stella Vu'><p><strong>Stella Vu</strong><br>Business Development Manager</p></div>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<div style="height:2em" aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph"><em>“<strong>Clinical trials: </strong>Having attended Clinical Outsourcing Group Nordics, BioSpain and the Barcelona Health Hub congress, my main takeaway is that sponsors are consolidating vendors and expect outsourcing partners that combine specialized regulatory expertise with very clear contractual, operational and financial structures.</em> <em>&nbsp;</em> <em>At Clinical Outsourcing Group Nordics, including my session, the focus was on how outsourcing models, contracts and project oversight need to be aligned so that responsibilities, risks, and escalation paths are transparent for both sponsor and service provider.</em> <em>&nbsp;</em></p>



<p class="wp-block-paragraph"><strong><em>Spain: </em></strong><em>In the Spain-focused events, the message was that the local ecosystem is growing fast, but still needs partners who can translate complex European requirements into clear service packages and predictable pricing, especially for small and medium biotechs using Spain as a strategic entry point to Europe.</em> <em>&nbsp;</em> </p>



<p class="wp-block-paragraph"><strong><em>Digital innovation: </em></strong><em>Across all meetings, digital innovation and artificial intelligence were very visible, with a particular interest in the potential of digital twins in clinical research, where sponsors see opportunities but still look for guidance on contractual frameworks, data governance and regulatory expectations.”</em> <em>&nbsp;</em><br></p>


<div class='author-details'><img src='/wp-content/themes/lumis-child/dist/img/content/Team/andres-aguilar-caro.jpg' width='450' height='450' loading='lazy' decoding='async' alt='Andrés Aguilar Caro'><p><strong>Andrés Aguilar Caro</strong><br>Head of Contracts and Proposals </p></div>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<div style="height:1em" aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading">Next Steps: Partner with Lumis</h2>



<p class="wp-block-paragraph">Ready to translate these insights into a decisive advantage for your business? We understand how the medtech and biotech industries are changing and can help you leverage these shifts to your advantage.</p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://lumisinternational.com/2025-conference-insights-what-industry-trends-may-impact-your-business/">2025 Conference Insights: What industry trends may impact your business?</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>KPI Snapshot &#038; Year in Review</title>
		<link>https://lumisinternational.com/kpi-snapshot-year-in-review/</link>
		
		<dc:creator><![CDATA[Heike Schoen]]></dc:creator>
		<pubDate>Mon, 15 Dec 2025 15:34:10 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://lumisinternational.com/?page_id=47005</guid>

					<description><![CDATA[<p>2025 was a year of very tangible progress for Lumis. While medical technology and biotechnology companies continued to navigate MDR, IVDR and complex EU market entry, our role became increasingly clear. We were asked to do more than explain regulations. We were asked to translate uncertainty into concrete decisions.</p>
<p>The post <a href="https://lumisinternational.com/kpi-snapshot-year-in-review/">KPI Snapshot &amp; Year in Review</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-full left-image rounded-corner-image"><img decoding="async" width="950" height="600" src="https://lumisinternational.com/wp-content/uploads/2025/12/lumis-kpi-growth-2025.jpg" alt="Abstract image related to growth of Lumis in 2025" class="wp-image-46999" srcset="https://lumisinternational.com/wp-content/uploads/2025/12/lumis-kpi-growth-2025.jpg 950w, https://lumisinternational.com/wp-content/uploads/2025/12/lumis-kpi-growth-2025-300x189.jpg 300w, https://lumisinternational.com/wp-content/uploads/2025/12/lumis-kpi-growth-2025-768x485.jpg 768w" sizes="(max-width: 950px) 100vw, 950px" /></figure>



<div style="height:2em" aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">2025 was a year of very tangible progress for Lumis. While medical technology and biotechnology companies continued to navigate MDR, IVDR and complex EU market entry, our role became increasingly clear. We were asked to do more than explain regulations. We were asked to translate uncertainty into concrete decisions.</p>



<p class="wp-block-paragraph">Throughout the year, our LinkedIn presence and website became an active extension of that work. Our community did not just grow in numbers. Engagement with our posts, campaigns and resources increased steadily, and interactions shifted from simple likes to informed questions and meaningful dialogue.</p>



<p class="wp-block-paragraph">We published a focused set of blog articles and more than forty social media pieces, each anchored in real client questions. Resources such as our CE marking checklist and our guides on European Authorized Representative responsibilities were downloaded and shared frequently, confirming that there is strong demand for practical, immediately usable guidance.</p>



<p class="wp-block-paragraph">The impact for us goes well beyond metrics. Our content is increasingly used as a reference by medical technology and biotechnology companies when they define regulatory strategies, refine internal procedures or brief their boards. This trust has a direct result. During 2025, we saw a clear increase in inbound requests, introductory calls and meeting invitations that started with one simple sentence: “We found you through your content.”</p>



<p class="wp-block-paragraph">Going into 2026, we are entering the year with three important assets. A more informed and engaged audience. A clearer position for Lumis as a regulatory and legal partner in Europe. And a stronger pipeline of conversations with innovators who see us not as a vendor, but as a long-term strategic counterpart.</p>



<p class="wp-block-paragraph">If 2025 has shown us anything, it is this. In periods of regulatory change, companies look for voices that are precise, honest and actionable. We are committed to being one of those voices, and to continue sharing insights that help our clients move from complexity to clarity.</p>



<p class="wp-block-paragraph">Thank you for being part of this journey. In 2026, we will keep raising the bar on the content, tools and guidance we provide.</p>
<p>The post <a href="https://lumisinternational.com/kpi-snapshot-year-in-review/">KPI Snapshot &amp; Year in Review</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Big Faces of Lumis and Team Moves</title>
		<link>https://lumisinternational.com/big-faces-of-lumis-and-team-moves/</link>
		
		<dc:creator><![CDATA[Heike Schoen]]></dc:creator>
		<pubDate>Mon, 15 Dec 2025 15:27:20 +0000</pubDate>
				<category><![CDATA[Company events]]></category>
		<guid isPermaLink="false">https://lumisinternational.com/?page_id=47001</guid>

					<description><![CDATA[<p>If we took a team picture at the beginning of 2025 and compared it with today, the difference would not only be in the number of faces. It would also be in how clearly each person knows what they contribute and how those roles connect across Lumis. This piece is a small snapshot of that change in people, not in org charts.</p>
<p>The post <a href="https://lumisinternational.com/big-faces-of-lumis-and-team-moves/">Big Faces of Lumis and Team Moves</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-full left-image rounded-corner-image"><img loading="lazy" decoding="async" width="950" height="600" src="https://lumisinternational.com/wp-content/uploads/2025/12/lumis-team-photo-2025.jpg" alt="Lumis team photo 2025" class="wp-image-47000" srcset="https://lumisinternational.com/wp-content/uploads/2025/12/lumis-team-photo-2025.jpg 950w, https://lumisinternational.com/wp-content/uploads/2025/12/lumis-team-photo-2025-300x189.jpg 300w, https://lumisinternational.com/wp-content/uploads/2025/12/lumis-team-photo-2025-768x485.jpg 768w" sizes="auto, (max-width: 950px) 100vw, 950px" /></figure>



<div style="height:2em" aria-hidden="true" class="wp-block-spacer"></div>



<p class="wp-block-paragraph">If we took a team picture at the beginning of 2025 and compared it with today, the difference would not only be in the number of faces. It would also be in how clearly each person knows what they contribute and how those roles connect across Lumis. This piece is a small snapshot of that change in people, not in org charts.</p>



<p class="wp-block-paragraph">This year, our team has not only grown, but it has also become more defined in how we work together. With Domingo Rodriguez joining Finance in July 2025, we gained someone who quietly brings order to numbers, invoices and closing routines. In Business Development, Stella Vu keeps opening doors and conversations, making sure Lumis is visible and approachable to sponsors who may only have heard our name in passing. On the operations side, Mahua Chatterjee has become a steady point of contact in day-to-day follow-up, making sure actions do not get lost between emails and time zones. And in the background of many of these movements, Nasim Moradi, as team assistant, is often the person who makes sure information, meetings and small but important details actually find their place.</p>



<p class="wp-block-paragraph">Around this group, our senior colleagues hold the frame. In Operations, Frauke Bach is our Senior Project Manager and the person many sponsors associate with Lumis when it comes to running a study. She keeps projects moving, balances expectations on all sides and is often the first to translate a complex situation into a practical next step. In Regulatory, Liam Spencer acts as Senior Regulatory Project Manager, taking responsibility for the bigger decisions, weighing options with clients and making sure our regulatory advice is consistent and defensible. From Contracts and Proposals, our Head of Contracts and Proposals, Andrés Aguilar, has assumed this role during 2025, connecting scope, price and responsibilities so that what we sign reflects what we can deliver and what our teams need to plan for.</p>



<p class="wp-block-paragraph">Some of these connections became very tangible when we met in Barcelona during our summer event. People who usually meet only on screen worked side by side, discussed real cases and aligned on how Finance, Operations, Regulatory, Business Development and Contracts can support each other more predictably. The result is not a new slogan, but a quieter change. It is easier to know whom to call, what to expect and how our individual roles contribute to the whole.</p>



<p class="wp-block-paragraph">We also introduced Mr and Mrs Device at MEDICA, a small internal joke with a serious background. Our growing presence in the medical device field comes from years of specialized work, not from a single conference. Mr. and Mrs. Device simply put a face on that momentum and remind us that even in a highly technical area, we are allowed a dry smile now and then.</p>



<p class="wp-block-paragraph">We close the year with a clearer structure and a team that is better connected across functions. This is possible because people did the work, and because our CEO, Heike Schön, consistently backed the decisions needed to get here. We also recognize the trust and support of our shareholders, who give us the room to think long term. With that foundation, we can step into next year with a realistic level of ambition and a team that is ready for the next stage of Lumis’ growth.</p>
<p>The post <a href="https://lumisinternational.com/big-faces-of-lumis-and-team-moves/">Big Faces of Lumis and Team Moves</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Navigating the Labyrinth: The CE-Marking Challenges for AiMD and SaMD in the EU</title>
		<link>https://lumisinternational.com/ce-marking-challenges-for-aimd-and-samd-in-the-eu/</link>
		
		<dc:creator><![CDATA[Liam Spencer]]></dc:creator>
		<pubDate>Mon, 01 Dec 2025 17:58:55 +0000</pubDate>
				<category><![CDATA[Medical device regulatory consulting & services]]></category>
		<guid isPermaLink="false">https://lumisinternational.com/?p=46988</guid>

					<description><![CDATA[<p>The European Union's Medical Device Regulation and the new Artificial Intelligence Act introduced a seismic shift for medical device companies. For developers of Software as a Medical Device (SaMD) and, specifically, Artificial Intelligence Medical Devices (AiMD), obtaining the coveted CE mark has become significantly more complex.</p>
<p>The post <a href="https://lumisinternational.com/ce-marking-challenges-for-aimd-and-samd-in-the-eu/">Navigating the Labyrinth: The CE-Marking Challenges for AiMD and SaMD in the EU</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">The European Union&#8217;s Medical Device Regulation (EU MDR 2017/745)<sup>1</sup> and the new Artificial Intelligence Act (AIA)<sup>2</sup> introduced a seismic shift for medical device companies. For developers of <strong>Software as a Medical Device (SaMD)</strong> and, specifically, <strong>Artificial Intelligence Medical Devices (AiMD)</strong>, obtaining the coveted CE mark has become significantly more complex.</p>



<figure class="wp-block-image size-full content_image"><img loading="lazy" decoding="async" width="950" height="600" src="https://lumisinternational.com/wp-content/uploads/2025/12/aimd-samd-illustration.jpg" alt="Illustration for AiMD and SaMD, showing a computer screen, a brain, a mobile device, a syringe and other elements linking technology to medical interests" class="wp-image-46987" srcset="https://lumisinternational.com/wp-content/uploads/2025/12/aimd-samd-illustration.jpg 950w, https://lumisinternational.com/wp-content/uploads/2025/12/aimd-samd-illustration-300x189.jpg 300w, https://lumisinternational.com/wp-content/uploads/2025/12/aimd-samd-illustration-768x485.jpg 768w" sizes="auto, (max-width: 950px) 100vw, 950px" /></figure>



<p class="wp-block-paragraph">Here are the key hurdles digital health manufacturers must overcome to achieve and maintain CE compliance.</p>



<h2 class="wp-block-heading">The Looming Presence of the EU AI Act</h2>



<p class="wp-block-paragraph">While the MDR is the law governing the CE mark, the forthcoming <strong>EU Artificial Intelligence (AI) Act</strong> adds an unprecedented new layer of regulatory complexity for high-risk AI applications—a category that includes most AiMD.</p>



<ul class="wp-block-list">
<li><strong>Dual Compliance:</strong> AiMD will likely need to comply with <strong>both</strong> the MDR (for safety and performance as a medical device) <strong>and</strong> the AI Act (for requirements related to data governance, transparency, robustness, and human oversight as a high-risk AI system).</li>



<li><strong>Transparency and Explainability (XAI):</strong> The AI Act introduces strict requirements for <strong>transparency</strong> and <strong>human oversight, </strong>particularly for high-risk AI systems (Article 13). Manufacturers will need to implement measures for <strong>Explainable AI (XAI)</strong>, allowing users to understand the model&#8217;s output and decision-making process, a technical challenge for complex deep learning models.</li>
</ul>



<h2 class="wp-block-heading">The Up-Classification Challenge</h2>



<p class="wp-block-paragraph">Under the previous Medical Device Directive (MDD), many low-risk SaMDs were <strong>Class I</strong> devices, allowing manufacturers to <strong>self-certify</strong> without the review of a Notified Body (NB).</p>



<ul class="wp-block-list">
<li><strong>The MDR Shift:</strong> The MDR introduced stricter, risk-based classification rules (Rule 11) for software. Given most SaMD/ AiMD are intended to support clinical decision making, most products will be at least <strong>Class IIa</strong> – therefore, requiring a <strong>Notified Body</strong> for Conformity Assessment. Manufacturers should also establish if the software functionality of a hardware device has its own medical purpose &#8211; thus, it is a medical device itself. Or does the software just drive/ influence the hardware (which may be considered an “accessory” under the MDR or In Vitro Diagnostic Regulation 2017/746 (IVDR))<sup>3</sup>.</li>



<li><strong>The Consequence:</strong> Manufacturers previously operating under self-certification must now undergo rigorous third-party audits, significantly increasing time-to-market and compliance costs. Furthermore, identifying a Notified Body designated for software conformity assessments with available resources and reasonable timeframes can be difficult.</li>
</ul>



<h2 class="wp-block-heading">Dynamic Algorithms vs. Static Documentation</h2>



<p class="wp-block-paragraph">AiMDs, particularly those employing <strong>Machine Learning (ML)</strong>, are designed to learn and adapt over time. This dynamic nature clashes with the MDR&#8217;s demand for static, controlled, and pre-market-approved documentation.</p>



<ul class="wp-block-list">
<li><strong>Algorithmic Modification:</strong> A core difficulty is demonstrating compliance when the algorithm&#8217;s performance changes after deployment (known as <strong>&#8220;algorithm drift&#8221;</strong>). Under MDR, any significant change or modification to the intended purpose or design may require a new UDI-DI and assessment by the Notified Body, resulting in a supplement to the CE-certificate or possibly requiring a new conformity assessment.</li>



<li><strong>The Burden of Proof:</strong> Regulators need assurance that new versions or updates do not negatively impact patient safety or clinical performance. Manufacturers must implement a quality management system (QMS) which captures these modifications under a <strong>change control mechanism</strong> that clearly defines what constitutes a &#8220;significant&#8221; change requiring NB notification versus a &#8220;non-significant&#8221; change that can be self-declared. This emphasizes the importance of tailoring the QMS to the product and not simply using available templates – as those that work for static hardware products may not be effective for dynamic machine learning platforms.</li>
</ul>



<h2 class="wp-block-heading">Enhanced Clinical Evidence Requirements</h2>



<p class="wp-block-paragraph">The MDR significantly raised the bar for demonstrating clinical safety and performance, a major hurdle for novel AiMD.</p>



<ul class="wp-block-list">
<li><strong>Rigor of the CER:</strong> The <strong>Clinical Evaluation Report (CER)</strong> must now provide robust, scientifically sound evidence demonstrating the device&#8217;s intended clinical benefit and an acceptable benefit-risk ratio. Furthermore, claiming equivalence between artificial intelligence platforms is difficult under the stricter MDR rules but also because AiMD are normally novel and unique. Additionally, equivalence is challenging given AiMD technologies can lack transparency (e.g. machine learning black boxes) and, as mentioned above, can be dynamic. On the other hand, SaMD and AiMD can have streamlined clinical evaluations via retrospective data analysis.</li>



<li><strong>Data Governance &amp; Bias:</strong> For AiMD, this extends to the data used for training and validation. Requirements exist in both the MDR/IVDR and the new Artificial Intelligence Act for data used to train the algorithm. Manufacturers must demonstrate that the <strong>datasets are representative</strong>, unbiased, and of high quality<sup>4</sup>.</li>
</ul>



<h2 class="wp-block-heading">Cybersecurity as a General Safety and Performance Requirement (GSPR)</h2>



<p class="wp-block-paragraph">For any connected SaMD or AiMD, <strong>cybersecurity</strong> is a unique but fundamental requirement.</p>



<ul class="wp-block-list">
<li><strong>GSPR 17:</strong> Annex I of the MDR (GSPR 17) explicitly requires devices with programmable electronic systems to be designed to ensure data and system security. This includes protecting against unauthorized access, data breaches, and ensuring the integrity of the clinical data the software processes.</li>



<li><strong>Artificial Intelligence Act (Article 15): </strong>This article states that high-risk devices must have cybersecurity in place not just for the software but also for associated assets (e.g. training data sets).</li>



<li><strong>General Data Protection Regulation (GDPR):</strong> Many SaMD and AiMD also process personal data. Therefore, under the GDPR, this data collected must be kept to a minimum and protected accordingly. The GDPR places requirements on data processing additional to security and privacy – for example, there must always be a lawful basis (Article 6) and data subject rights respected (Chapter III)<sup>5</sup>. Furthermore, compliance to GDPR may apply from early development so could be relevant before the MDR CE-marking process.</li>



<li><strong>Continuous Monitoring:</strong> Since software vulnerabilities are constantly discovered, manufacturers must implement a <strong>proactive system</strong> for monitoring, patching, and updating the device&#8217;s security throughout its entire lifecycle, managed through the Post-Market Surveillance (PMS) system.</li>
</ul>



<h2 class="wp-block-heading">Conclusion: Strategic Compliance is Key</h2>



<p class="wp-block-paragraph">The transition to EU MDR—compounded by the emergence of the AI Act—presents profound challenges for SaMD and AiMD developers. The path to CE marking is now longer, more resource-intensive, and demands a level of continuous compliance management far exceeding previous standards.</p>



<p class="wp-block-paragraph">To succeed, manufacturers must adopt a <strong>proactive, strategy-first approach</strong>:</p>



<ol start="1" class="wp-block-list">
<li><strong>Early Classification:</strong> Accurately classify the device early to identify all the applicable regulations and standards. Confirm whether Notified Body involvement is required and select the conformity assessment route which aligns with all applicable regulations (e.g. MDR and AIA).</li>



<li><strong>AI-Centric QMS:</strong> Integrate AI-specific requirements (like data management, algorithm change control, cybersecurity, etc) directly into the Quality Management System (QMS).</li>



<li><strong>Invest in CER:</strong> Prioritize rigorous, well-documented clinical validation and post-market clinical follow-up (PMCF) from day one. Retrospective data can be useful to reduce clinical development costs; however, the data must be representative of the final intended use population.</li>
</ol>



<h2 class="wp-block-heading">How can Lumis help?</h2>



<p class="wp-block-paragraph">Lumis International is a regulatory affairs consultancy specializing in supporting small and medium-sized medical device companies.</p>



<p class="wp-block-paragraph">Our experts possess a unique strength in the rapidly evolving digital health sector, with an established niche in securing the CE-mark for Software as a Medical Device (SaMD) and Artificial Intelligence Medical Device (AiMD) products.</p>



<p class="wp-block-paragraph">We provide both strategic and operational support to seamlessly streamline your route to compliance, accelerating your product&#8217;s market entry.</p>



<p class="wp-block-paragraph">Do you want to CE-mark your digital health product? Contact us to discuss your project.</p>



<h2 class="wp-block-heading">References</h2>



<ol class="wp-block-list">
<li>Medical Devices Regulation (EU) 2017/745 of the European Parliament and of the Council of 5&nbsp;April 2017 on medical devices <a href="https://eur-lex.europa.eu/eli/reg/2017/745/oj/eng#anx_IX">https://eur-lex.europa.eu/eli/reg/2017/745/oj/eng#anx_IX</a></li>



<li>Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024 laying down harmonised rules on artificial intelligence. <a href="https://eur-lex.europa.eu/eli/reg/2024/1689/oj/eng">https://eur-lex.europa.eu/eli/reg/2024/1689/oj/eng</a></li>



<li>MDCG 2019-11 Rev.1. Guidance on Qualification and Classification of Software in Regulation (EU) 2017/745 – MDR and Regulation (EU) 2017/746 – IVDR. October 2019. June 2025 rev.1. <a href="https://health.ec.europa.eu/document/download/b45335c5-1679-4c71-a91c-fc7a4d37f12b_en?filename=mdcg_2019_11_en.pdf">https://health.ec.europa.eu/document/download/b45335c5-1679-4c71-a91c-fc7a4d37f12b_en?filename=mdcg_2019_11_en.pdf</a></li>



<li>MDCG&nbsp; 2025-6&nbsp; Interplay between the Medical&nbsp;&nbsp; Devices Regulation (MDR) &amp; In vitro Diagnostic Medical Devices Regulation (IVDR) and the Artificial Intelligence Act (AIA). June 2025. <a href="https://health.ec.europa.eu/document/download/b78a17d7-e3cd-4943-851d-e02a2f22bbb4_en?filename=mdcg_2025-6_en.pdf">https://health.ec.europa.eu/document/download/b78a17d7-e3cd-4943-851d-e02a2f22bbb4_en?filename=mdcg_2025-6_en.pdf</a></li>



<li>Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data. <a href="https://eur-lex.europa.eu/eli/reg/2016/679/oj/eng">https://eur-lex.europa.eu/eli/reg/2016/679/oj/eng</a></li>
</ol>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://lumisinternational.com/ce-marking-challenges-for-aimd-and-samd-in-the-eu/">Navigating the Labyrinth: The CE-Marking Challenges for AiMD and SaMD in the EU</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>How Small Medical Device Companies Can Successfully Go Global</title>
		<link>https://lumisinternational.com/how-small-medical-device-companies-can-successfully-go-global/</link>
		
		<dc:creator><![CDATA[Liam Spencer]]></dc:creator>
		<pubDate>Sat, 15 Nov 2025 08:34:36 +0000</pubDate>
				<category><![CDATA[Global representative medical devices]]></category>
		<guid isPermaLink="false">https://lumisinternational.com/?p=46979</guid>

					<description><![CDATA[<p>Global expansion for a medical device SME isn't about simply selling a product in a new country; it's a strategic undertaking that requires a series of critical decisions. Here are key decisions a medical device SME should make before going global.</p>
<p>The post <a href="https://lumisinternational.com/how-small-medical-device-companies-can-successfully-go-global/">How Small Medical Device Companies Can Successfully Go Global</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><em><strong>Key Points:</strong></em></p>



<ul class="wp-block-list">
<li>Global expansion enables long-term, robust growth</li>



<li>Expanding into new markets is complex and risky</li>



<li>A multi-disciplinary team is required for reliable, strategic planning</li>



<li>With the correct planning, global expansion is an achievable goal for even small medical device companies with limited resources.</li>
</ul>



<figure class="wp-block-image size-full content_image"><img loading="lazy" decoding="async" width="950" height="633" src="https://lumisinternational.com/wp-content/uploads/2025/11/world-map-with-coloured-pins.jpg" alt="A map of the world in colour with various countries marked with pins. A pin marking Brazil is in the centre." class="wp-image-46978" srcset="https://lumisinternational.com/wp-content/uploads/2025/11/world-map-with-coloured-pins.jpg 950w, https://lumisinternational.com/wp-content/uploads/2025/11/world-map-with-coloured-pins-300x200.jpg 300w, https://lumisinternational.com/wp-content/uploads/2025/11/world-map-with-coloured-pins-768x512.jpg 768w" sizes="auto, (max-width: 950px) 100vw, 950px" /></figure>



<p class="wp-block-paragraph">Global expansion for a medical device SME isn&#8217;t about simply selling a product in a new country; it&#8217;s a strategic undertaking that requires a series of critical decisions. The choices you make before you even enter a new market will determine your success and sustainability. Here are key decisions a medical device SME should make before going global.</p>



<h2 class="wp-block-heading">1. Commercial Viability &nbsp;</h2>



<p class="wp-block-paragraph">Firstly, you should decide on which market(s) offer commercial opportunities. However, you should limit your market choice to align with your available resources. Entering a new market takes considerable resources and given most device companies are small-to-medium enterprises, it is often appropriate to prioritize your global expansion to one or two markets at a time. This minimizes risks whilst maximizing your chance of successful market access.</p>



<ul class="wp-block-list">
<li><strong>Market Research:</strong> Conduct a comprehensive analysis of potential markets. Look at the <strong>prevalence of the condition</strong> your device treats, the <strong>size of the patient population</strong>, and the <strong>demographics</strong> of the country. Consider the <strong>competitive landscape</strong>: Are there similar devices already on the market? How successful are the competitors in this market?</li>



<li><strong>Economic Viability and Reimbursement:</strong> Assess the economic conditions of the target country. Is there a strong healthcare budget? Does your product fit into the current care pathway and the market’s healthcare system? Are there <strong>reimbursement policies</strong> that favor your device? Understanding the local reimbursement system is crucial for ensuring that hospitals and clinics can actually afford to use your product.</li>



<li><strong>Political and Cultural Stability:</strong> Look for a stable political environment and a culture that is open to adopting new medical technologies. Unstable political climates can lead to sudden, disruptive regulatory changes and supply chain issues.</li>



<li><strong>Intellectual Property (IP) Protection:</strong> Patent protection is limited to geographical regions, what is protected in one market may not be protected in another. Therefore, check your IP is suitably protected before entering a market.</li>
</ul>



<h2 class="wp-block-heading">2. Developing a Regulatory Strategy</h2>



<p class="wp-block-paragraph">The regulatory environment for medical devices is complex and varies from country to country. Your regulatory strategy is your roadmap to compliance.</p>



<ul class="wp-block-list">
<li><strong>Classification:</strong> Correctly classify your device in the target market. Many countries’ classification system is based on the International Medical Device Regulators Forum (IMDRF)<sup>1</sup>. However, the process of classification can differ significantly – e.g. between Japan and the EU. And even for similar processes, like with the EU and Australia, the product class can still differ. Therefore, make sure you classify your product in each target market according to their regulations.</li>



<li><strong>Submission Pathway:</strong> Identify the correct regulatory submission pathway for your device. This could be a 510(k) clearance in the U.S., a CE Mark in the EU, or a specific submission to a local authority like Japan’s PMDA or Brazil&#8217;s ANVISA. In some countries, foreign regulatory approvals (e.g. CE-mark) are recognized and can streamline the submission process – e.g. Australia. Whereas, in other countries their regulatory process is distinct and more involved. Knowing the submission workload during strategic planning can help confirm the feasibility of entering the target market.</li>



<li><strong>Evidence and Documentation:</strong> Determine what clinical and non-clinical evidence is required. Some countries may accept data from U.S. or EU trials and laboratories, while others may demand <strong>local data </strong>to prove safety and efficacy in their population. A well-organized technical file and quality management system are non-negotiable for all regions.</li>



<li><strong>In</strong>&#8211;<strong>Country Representation: </strong>Many markets require a local representative for product registration and market access (e.g. USA, EU, China, India, etc.), this entity is sometimes known as an authorized representative. The in-country representative acts as a liaison between you and the regulatory authority, however, the representative’s responsibilities can vary by jurisdiction. For example, the EU authorized representative (EU-REP) has more responsibility than representatives in some other markets. Sometimes distributors can act as in-country representatives which can provide a convenient two-in-one solution; however, it may limit your flexibility in the future in changing your distribution network.</li>
</ul>



<h2 class="wp-block-heading">3. Selecting a Go-to-Market Model</h2>



<p class="wp-block-paragraph">How will you actually get your device into the hands of healthcare professionals and patients? Your go-to-market model needs to be carefully chosen.</p>



<ul class="wp-block-list">
<li><strong>Direct Sales:</strong> This involves building your own sales team and distribution network in the target country. It offers the most control but is expensive and time-consuming. It&#8217;s often most feasible for high-margin, high-volume products.</li>



<li><strong>Distributors:</strong> Partnering with local distributors is a very common strategy for SMEs. Distributors have existing relationships, local market knowledge, and established logistics. However, you must conduct thorough due diligence to ensure they are reputable and have expertise in your device and therapeutic area. As mentioned above, it is often advantageous to have an independent in-country representative, separate from the distributor, to provide you with greater control over your distribution and commercial operations.</li>



<li><strong>Hybrid Models:</strong> You can start with a distributor and then transition to a direct sales model once you have a strong foothold. This is a great way to scale your presence over time.</li>
</ul>



<h2 class="wp-block-heading">4. Crafting a Localized Strategy</h2>



<p class="wp-block-paragraph">Your product, marketing, and messaging must be tailored to the local market. What works in one country may not resonate in another.</p>



<ul class="wp-block-list">
<li><strong>Localization vs. Translation:</strong> Localization is more than just translating your user manuals and marketing materials. It involves adapting your product to local standards, including power plugs, units of measurement, and even user interface design.</li>



<li><strong>Supply Chain:</strong> Many medical devices require specific storage conditions (e.g., temperature control). Maintaining these conditions throughout a complex international supply chain adds layers of difficulty and expense. Consider finding a suitable logistics partner for this role.</li>



<li><strong>Marketing and Sales:</strong> Develop a marketing plan that speaks to the specific needs and values of the target audience. The sales approach should also be adapted to local business culture and customs.</li>



<li><strong>Post-Market Surveillance:</strong> Plan for robust post-market activities, including adverse event reporting and user feedback systems, in compliance with local regulations. This is crucial for maintaining market access and demonstrating a commitment to patient safety.</li>
</ul>



<h2 class="wp-block-heading">Summary</h2>



<p class="wp-block-paragraph">Global expansion is a long-term goal for many SME medical device companies but it can be considered unachievable due to the risks, challenges, and complexity. To mitigate these difficulties, careful planning involving a multi-disciplinary team is essential. Commercial, regulatory, distribution, sales, and supply chain are just some factors which must be considered to ensure the expansion will yield a return on investment. Furthermore, a key aspect of any global expansion, especially for SMEs, is partnering with compatible companies who can facilitate your expansion. Resource management ensures the expansion plan’s scope is aligned with available capacity and, where necessary, activities are outsourced (e.g. distributors, logistics, translations).</p>



<p class="wp-block-paragraph">Global expansion offers long-term opportunities for medical device companies, particularly SMEs. It expands revenue streams, de-risks overreliance on individual markets, and improves brand awareness and reputation. All these benefits are conducive to robust long-term growth and with a multi-disciplinary strategic plan, they are an achievable goal.</p>



<h2 class="wp-block-heading">How Can Lumis Help?</h2>



<p class="wp-block-paragraph">Lumis International is a consultancy specializing in representative services and medical device regulatory affairs. We have been representing medical device companies for over 10 years and have a team of expert medical device regulatory professionals. In addition to regulatory planning and consultancy, we provide global in-country representative services in 18 markets, across 5 continents. We also have partners in distribution, reimbursement, importing, and development to facilitate global expansion. Hence, Lumis can act as a strategic partner to unlock your global growth.&nbsp;</p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://lumisinternational.com/how-small-medical-device-companies-can-successfully-go-global/">How Small Medical Device Companies Can Successfully Go Global</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Global In-Country Representation: Convert Your Global Ambition to Global Reality</title>
		<link>https://lumisinternational.com/global-in-country-representation-convert-your-global-ambition-to-global-reality/</link>
		
		<dc:creator><![CDATA[Liam Spencer]]></dc:creator>
		<pubDate>Tue, 28 Oct 2025 17:19:22 +0000</pubDate>
				<category><![CDATA[Global representative medical devices]]></category>
		<guid isPermaLink="false">https://lumisinternational.com/?p=46970</guid>

					<description><![CDATA[<p>Navigating the complex landscape of medical device regulations across different countries can be a significant challenge for any company. To help our clients overcome these challenges, we are excited to announce the expansion of our in-country representative services to include key markets worldwide.</p>
<p>The post <a href="https://lumisinternational.com/global-in-country-representation-convert-your-global-ambition-to-global-reality/">Global In-Country Representation: Convert Your Global Ambition to Global Reality</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<h2 class="wp-block-heading">Your Global Expansion, Our Local Expertise</h2>



<p class="wp-block-paragraph">Navigating the complex landscape of medical device regulations across different countries can be a significant challenge for any company. As global markets continue to evolve, so do the requirements for market entry and in-country representation (sometimes referred as “authorized representative”). To help our clients overcome these hurdles and expand their reach, we are excited to announce the expansion of our in-country representative services to include key markets worldwide.</p>



<figure class="wp-block-image size-full content_image"><img loading="lazy" decoding="async" width="950" height="541" src="https://lumisinternational.com/wp-content/uploads/2025/10/global-representation-globe-in-hand.jpg" alt="Global representation for medical devices. Image of a hand holding a globe showing a map of the world" class="wp-image-46974" srcset="https://lumisinternational.com/wp-content/uploads/2025/10/global-representation-globe-in-hand.jpg 950w, https://lumisinternational.com/wp-content/uploads/2025/10/global-representation-globe-in-hand-300x171.jpg 300w, https://lumisinternational.com/wp-content/uploads/2025/10/global-representation-globe-in-hand-768x437.jpg 768w" sizes="auto, (max-width: 950px) 100vw, 950px" /></figure>



<h2 class="wp-block-heading">The Challenge of Global Medical Device Market Entry</h2>



<p class="wp-block-paragraph">For a medical device company, securing a CE mark or an FDA 510(k) clearance is a key milestone, but it&#8217;s often just the first step. True global success requires a strategic approach to market access, which includes fulfilling the specific in-country representation mandates of different regulatory bodies. Each country—from the U.S. and Canada to Australia and Japan—has its own set of rules, documentation requirements, and submission processes.</p>



<p class="wp-block-paragraph">A failure to understand and comply with these local requirements can lead to significant setbacks. Regulatory delays can stall your product launch, compliance issues can lead to costly fines, and without a local point of contact, you risk being out of touch with crucial updates from local health authorities. With 90-95% of medical device companies being Small-to-Medium Enterprises (SMEs)<sup>1</sup>, most manufacturers do not have the capacity or infrastructure to establish themselves across global markets.</p>



<h2 class="wp-block-heading">Introducing Our Expanded In-Country Representation Services</h2>



<p class="wp-block-paragraph">To address this growing need, we are extending our in-country representation offering. Our new service now covers a comprehensive list of countries, including:</p>



<ul class="wp-block-list">
<li><strong>North America: </strong>Canada, Mexico, United States</li>



<li><strong>South America: </strong>Brazil, Colombia</li>



<li><strong>Europe: </strong>European Union, United Kingdom</li>



<li><strong>Australia: </strong>Australia</li>



<li><strong>Asia: </strong>China, Hong Kong, Indonesia, India, Japan, Malaysia, Singapore, Thailand, Vietnam</li>
</ul>



<p class="wp-block-paragraph">Our expanded service is designed to be a seamless extension of your team, providing the local presence and regulatory knowledge you need to succeed. We handle the intricacies of local regulations, allowing you to focus on innovation and business growth.</p>



<h2 class="wp-block-heading">Why Partner with Our Regulatory Services Team?</h2>



<p class="wp-block-paragraph">Choosing the right partner for your in-country representation is critical. Our team offers:</p>



<ul class="wp-block-list">
<li><strong>Deep Local Expertise:</strong> We possess extensive knowledge of each country&#8217;s specific regulatory environment, ensuring your device remains compliant.</li>



<li><strong>Streamlined Market Access:</strong> We handle the intricate local processes, from device registration and technical file submissions to supporting post-market surveillance and adverse event reporting. This streamlined approach minimizes delays and helps you bring your products to market faster, giving you a crucial competitive advantage.</li>



<li><strong>Cost-Effective Solution:</strong> Establishing a physical office or hiring dedicated regulatory staff in multiple countries is often prohibitively expensive. Our service provides a flexible, scalable, and cost-effective alternative that enables your global expansion.</li>



<li><strong>Strong Network:</strong> We have a range of partners worldwide from Contract Research Organizations to distributors and importing experts who can help achieve your global commercial goals.</li>



<li><strong>Risk Mitigation:</strong> We help you identify and mitigate potential compliance risks, protecting your brand reputation.</li>
</ul>



<h2 class="wp-block-heading">Your Global Regulatory Partner</h2>



<p class="wp-block-paragraph">Whether you are a startup aiming to enter your first international market or an established company seeking to expand your global footprint, our expanded in-country representation services are here to support you. We are committed to being your reliable partner, providing the regulatory content and strategic guidance you need to navigate the global medical device landscape with confidence.</p>



<p class="wp-block-paragraph">Contact us to learn how our services can help achieve your global market goals.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading">References</h2>



<ol class="wp-block-list">
<li>The European Medical Technology Industry in figures 2021. MedTech Europe. <a href="http://www.medtecheurope.org/wp-content/uploads/2021/06/medtech-europe-facts-and-figures-2021.pdf">www.medtecheurope.org/wp-content/uploads/2021/06/medtech-europe-facts-and-figures-2021.pdf</a></li>
</ol>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://lumisinternational.com/global-in-country-representation-convert-your-global-ambition-to-global-reality/">Global In-Country Representation: Convert Your Global Ambition to Global Reality</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Why You Need a Legal Representative for Clinical Trials in Europe</title>
		<link>https://lumisinternational.com/why-you-need-a-legal-representative-for-clinical-trials-in-europe/</link>
		
		<dc:creator><![CDATA[Heike Schoen]]></dc:creator>
		<pubDate>Mon, 01 Sep 2025 08:47:00 +0000</pubDate>
				<category><![CDATA[Legal representative clinical trials]]></category>
		<guid isPermaLink="false">https://lumisinternational.com/?p=46925</guid>

					<description><![CDATA[<p>If your company is based outside the EU or EEA and you're planning to conduct a clinical trial in Europe, there's one thing you absolutely need to have in place before you get started: a legal representative. Here we explore the reasons for this and the options available.</p>
<p>The post <a href="https://lumisinternational.com/why-you-need-a-legal-representative-for-clinical-trials-in-europe/">Why You Need a Legal Representative for Clinical Trials in Europe</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">If your company is based outside the EU or EEA and you´re planning to conduct a clinical trial in Europe, there&#8217;s one thing you <em>absolutely</em> need to have in place before you get started: a <strong>legal representative</strong>.</p>



<figure class="wp-block-image size-full content_image"><img loading="lazy" decoding="async" width="950" height="534" src="https://lumisinternational.com/wp-content/uploads/2025/09/eu-flags.jpg" alt="EU flags in front of large office building" class="wp-image-46923" srcset="https://lumisinternational.com/wp-content/uploads/2025/09/eu-flags.jpg 950w, https://lumisinternational.com/wp-content/uploads/2025/09/eu-flags-300x169.jpg 300w, https://lumisinternational.com/wp-content/uploads/2025/09/eu-flags-768x432.jpg 768w" sizes="auto, (max-width: 950px) 100vw, 950px" /></figure>



<p class="wp-block-paragraph">This isn’t just a formality—it’s a regulatory requirement under EU law. And more importantly, it’s key to running a smooth, compliant, and ethically sound study in the European Union.</p>



<p class="wp-block-paragraph">Let’s break down what this role is, why it matters, and what you need to know.</p>



<h2 class="wp-block-heading">What Is a Legal Representative?</h2>



<p class="wp-block-paragraph">A legal representative is an individual or organization based in the EU/EEA who acts on behalf of a clinical trial sponsor located outside the region. Their role is mandated by the <strong>EU Clinical Trials Regulation (EU CTR 536/2014)</strong>, which governs how clinical trials are conducted across EU member states.</p>



<p class="wp-block-paragraph">In short, if you&#8217;re a sponsor from outside the EU/EEA, you must have a legal representative established <em>within</em> the EU/EEA in order to gain approval for your trial.</p>



<h2 class="wp-block-heading">Why Is This Required?</h2>



<p class="wp-block-paragraph">The legal representative ensures that the sponsor stays compliant with European laws and acts as the <strong>main point of contact</strong> between the sponsor and regulatory authorities. Here’s why that matters:</p>



<p class="wp-block-paragraph"><strong>1. They Provide Legal Accountability</strong></p>



<p class="wp-block-paragraph">The legal representative is <strong>jointly and severally liable</strong> with the sponsor for ensuring the trial is conducted according to EU regulations. That means they share legal responsibility for participant safety and compliance. It’s a safeguard for both patients and the regulatory system.</p>



<p class="wp-block-paragraph"><strong>2. They Handle Communications with EU Authorities</strong></p>



<p class="wp-block-paragraph">From submitting applications via the Clinical Trials Information System (CTIS) to managing safety reports and responding to regulatory queries, the legal representative is your official <strong>voice within the EU</strong>.</p>



<p class="wp-block-paragraph"><strong>3. They Help Ensure Participant Safety</strong></p>



<p class="wp-block-paragraph">European regulations put participant rights and safety first. The legal representative plays a key role in making sure all ethical and safety requirements, like informed consent and adverse event reporting—are respected in every participating country.</p>



<p class="wp-block-paragraph"><strong>4. They Navigate Local Requirements</strong></p>



<p class="wp-block-paragraph">Even though the EU CTR harmonizes clinical trial processes across Europe, each country may still have local expectations or procedures. A legal representative with EU experience can <strong>help avoid delays</strong> and ensure your trial runs smoothly across borders.</p>



<p class="wp-block-paragraph"><strong>5. They Assist with Liability and Insurance</strong></p>



<p class="wp-block-paragraph">In the event of a complaint or legal action, the legal representative may serve as the <strong>responsible party</strong> in the EU. They also ensure proper insurance and indemnification are in place, which is a common prerequisite for regulatory approval.</p>



<h2 class="wp-block-heading">Who Can Be a Legal Representative?</h2>



<p class="wp-block-paragraph">You have a few options here:</p>



<ul class="wp-block-list">
<li>An EU-based <strong>affiliate or subsidiary</strong> of your company</li>



<li>A <strong>legal services provider</strong> with experience in clinical trials</li>



<li>An individual <strong>consultant</strong></li>
</ul>



<p class="wp-block-paragraph">The best choice depends on your internal resources, the complexity of your trial, and how much local support you need.</p>



<h2 class="wp-block-heading">Final Thoughts</h2>



<p class="wp-block-paragraph">Having a legal representative is more than checking a box—it’s about building trust, ensuring compliance, and protecting participants.</p>



<p class="wp-block-paragraph">If you&#8217;re considering conducting clinical trials in Europe, partnering with the right legal representative is one of the most important steps you can take.</p>



<p class="wp-block-paragraph">Need help finding or appointing a legal representative in the EU? We can help guide you through the process. Let&#8217;s talk.</p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://lumisinternational.com/why-you-need-a-legal-representative-for-clinical-trials-in-europe/">Why You Need a Legal Representative for Clinical Trials in Europe</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>A Vigilant Ally – How Authorised Representatives Support Vigilance Activities</title>
		<link>https://lumisinternational.com/how-authorised-representatives-support-vigilance-activities/</link>
		
		<dc:creator><![CDATA[Liam Spencer]]></dc:creator>
		<pubDate>Thu, 20 Feb 2025 13:05:29 +0000</pubDate>
				<category><![CDATA[Authorized representative medical devices]]></category>
		<guid isPermaLink="false">https://lumisinternational.com/?p=46578</guid>

					<description><![CDATA[<p>For medical device manufacturers outside the EU, Authorized Representatives are crucial for navigating the complexities of the MDR and IVDR. Authorised representatives provide essential support for vigilance activities and play a key role in supporting CAPA processes. Authorised representative involvement strengthens compliance and communication, allowing manufacturers to focus more on innovation whilst maintaining the highest level of safety and performance.</p>
<p>The post <a href="https://lumisinternational.com/how-authorised-representatives-support-vigilance-activities/">A Vigilant Ally – How Authorised Representatives Support Vigilance Activities</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Medical device manufacturers are responsible for the safety and performance of their products- but for those outside the European Union, an Authorised Representative (AR) becomes a critical partner for success.</p>



<p class="wp-block-paragraph">Acting as the bridge between manufacturers and regulators, authorised representatives play a significant role in post-market surveillance, vigilance activities, and the implementation of Corrective and Preventative Actions (CAPA).</p>



<p class="wp-block-paragraph">This article explores how authorised representatives help manufacturers stay compliant under the Medical Device Regulation (EU) 2017/745 (“MDR”) and the In Vitro Diagnostic Regulation (EU) 2017/746 (“IVDR”). &nbsp;</p>



<figure class="wp-block-image size-full content_image"><img loading="lazy" decoding="async" width="951" height="634" src="https://lumisinternational.com/wp-content/uploads/2025/02/surgical-instruments-operating-theatre.jpg" alt="Surgical instruments in an operating theatre" class="wp-image-46577"/></figure>



<h2 class="wp-block-heading">Understanding the Roles:</h2>



<p class="wp-block-paragraph">Before diving into the specifics, it&#8217;s essential to understand the core responsibilities:</p>



<ul class="wp-block-list">
<li><strong>Manufacturer:</strong> Holds the primary responsibility for device safety and performance, including post-market surveillance and CAPA implementation.</li>



<li><strong>Authorised Representative (AR):</strong> Acts as the manufacturer&#8217;s representative within the European Union, responsible for communication with regulators, storing documentation, and fulfilling certain regulatory obligations. &nbsp;</li>



<li><strong>Vigilance:</strong> The systematic process of monitoring medical devices post-market to identify and investigate adverse events and trends.</li>



<li><strong>CAPA:</strong> A systematic process to identify, address, and prevent the recurrence of nonconformities or other quality issues related to medical devices. &nbsp;</li>
</ul>



<p class="wp-block-paragraph">Even though the non-EU manufacturer has ultimate responsibility for the post-market surveillance system, their authorised representative is a key partner in supporting their activities.</p>



<h2 class="wp-block-heading">How do Authorised Representatives Strengthen Vigilance?</h2>



<p class="wp-block-paragraph">ARs provide invaluable support to manufacturers in managing vigilance cases, including:</p>



<ul class="wp-block-list">
<li><strong>Reporting Adverse Events:</strong> Authorised representatives are a main contact for receiving adverse events (e.g. from patients, healthcare professionals, users). They also can support manufacturers with compiling incident reports and submitting them to the authorities. Therefore, ARs ensure faster, more complete vigilance reporting.</li>



<li><strong>Handling Regulatory Communication:</strong> Authorised representatives act as the manufacturer’s official liaison, responding to authority inquiries, providing additional documentation, and representing the company in meetings or investigations. Their local presence and understanding of the regulatory landscape are invaluable in these interactions. &nbsp;</li>



<li><strong>Trend Analysis:</strong> ARs can assist manufacturers in identifying trends in non-serious incidents. By assisting in the compilation and analysis of vigilance data, authorised representatives help manufacturers proactively identify potential safety risks and implement appropriate measures, in accordance with Article 88 MDR/ Article 83 IVDR.</li>



<li><strong>Supporting Periodic Summary Reporting:</strong> For certain serious incidents, authorised representatives can help prepare periodic summary reports, ensuring proportionate and compliant management of known and characterised serious incidents.</li>



<li><strong>Maintaining Vigilance Records:</strong> Authorised representatives maintain vigilance records, promoting compliance with regulatory requirements and facilitating audits.</li>
</ul>



<h2 class="wp-block-heading">How can Authorised Representatives support CAPA implementation?</h2>



<p class="wp-block-paragraph">The AR&#8217;s role extends beyond reporting and communication to supporting the manufacturer in the CAPA process:</p>



<ul class="wp-block-list">
<li><strong>Navigating Regulations:</strong> Authorised representatives possess a deep understanding of the regulatory requirements related to medical device CAPAs. They guide manufacturers, ensuring the right documentation, timelines, and procedures are met. &nbsp;</li>



<li><strong>Supporting Communication:</strong> Authorised representatives liaise with manufacturers, distributors, and healthcare facilities. This ensures relevant parties are informed and involved in the process. &nbsp;</li>



<li><strong>Monitoring CAPA Effectiveness:</strong> Whilst the manufacturer owns the CAPA, the authorised representative can assist in monitoring the implementation and impact of corrective actions. They can gather feedback from distributors and users to assess whether the actions have been effective in addressing the root cause.</li>



<li><strong>Supporting Field Corrective Actions:</strong> In cases requiring field corrective actions, such as recalls or device modifications, the AR coordinates directly with local authorities to execute actions quickly and efficiently.</li>
</ul>



<h2 class="wp-block-heading">Benefits of Authorised Representative Involvement:</h2>



<p class="wp-block-paragraph">The involvement of an authorised representative in vigilance and CAPA processes offers multiple benefits:</p>



<ul class="wp-block-list">
<li><strong>Stronger Compliance:</strong> ensure compliance with regulations, protecting patients and users while minimizing regulatory risks. &nbsp;</li>



<li><strong>Enhanced Communication:</strong> facilitate clear and effective communication with regulatory authorities and other stakeholders. &nbsp;</li>



<li><strong>Faster Response Times:</strong> respond quickly to adverse events and regulatory inquiries.</li>



<li><strong>Reduced Burden on Manufacturers:</strong> free manufacturers to focus more on product innovation and manufacturing.</li>
</ul>



<h2 class="wp-block-heading">Conclusion:</h2>



<p class="wp-block-paragraph">Authorised Representatives are key for non-EU manufacturers to fulfil their vigilance obligations. Their expertise in vigilance activities and their direct communication with regulators improves device safety and compliance.</p>



<p class="wp-block-paragraph">By leveraging the expertise and local knowledge of authorised representatives, manufacturers can effectively manage post-market surveillance and maintain the highest standards of product safety and performance.</p>



<p class="wp-block-paragraph">The support provided by authorised representatives also creates efficiencies by streamlining vigilance activities, allowing the manufacturer to focus on product optimisation and commercialisation.&nbsp;&nbsp;</p>
<p>The post <a href="https://lumisinternational.com/how-authorised-representatives-support-vigilance-activities/">A Vigilant Ally – How Authorised Representatives Support Vigilance Activities</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Beyond Compliance: Transform Your Authorized Representative into a Strategic Partner</title>
		<link>https://lumisinternational.com/beyond-compliance-transform-your-authorized-representative-into-a-strategic-partner/</link>
		
		<dc:creator><![CDATA[Liam Spencer]]></dc:creator>
		<pubDate>Fri, 31 Jan 2025 07:55:00 +0000</pubDate>
				<category><![CDATA[Authorized representative medical devices]]></category>
		<guid isPermaLink="false">https://lumisinternational.com/?p=46374</guid>

					<description><![CDATA[<p>Authorised Representatives (EC-REP) can be strategic partners and not just a compliance necessity. A good EC-REP provides regulatory insights, strengthens supply chains, supports post-market activities, and offers access to expert networks. Therefore, choosing the right EC-REP is crucial for EU market success.</p>
<p>The post <a href="https://lumisinternational.com/beyond-compliance-transform-your-authorized-representative-into-a-strategic-partner/">Beyond Compliance: Transform Your Authorized Representative into a Strategic Partner</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Selecting an authorized representative (EC-REP) is a critical step to entering the market for non-EU medical device manufacturers.</p>



<p class="wp-block-paragraph">Although many companies consider this a compliance “tick box” exercise, a proactive approach can transform this relationship into a powerfully strategic one.</p>



<p class="wp-block-paragraph">This article highlights how to leverage your EC-REP for valuable insights, improved efficiency, and to gain a competitive advantage.</p>



<figure class="wp-block-image size-full content_image"><img loading="lazy" decoding="async" width="951" height="634" src="https://lumisinternational.com/wp-content/uploads/2025/02/authorized-rep-beyond-compliance.jpg" alt="Map of Europe centred around southern Germany" class="wp-image-46364"/></figure>



<h2 class="wp-block-heading">What is an EC-REP?</h2>



<p class="wp-block-paragraph">First, let’s clarify what an authorized representative/ EC-REP is. According to Article 11 (1) of the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), any manufacturer located outside the EU must appoint an EC-REP before placing their device(s) on the market.</p>



<p class="wp-block-paragraph">The responsibilities of the EC-REP are listed in Article 11, some of the activities include:</p>



<ul class="wp-block-list">
<li><strong>Verifying </strong>the device’s documentation and Declaration of Conformity exist and have undergone the correct conformity assessment</li>



<li><strong>Storing technical documentation </strong>to provide to competent authorities, upon request</li>



<li><strong>Registration – </strong>ensure the manufacturer and device are registered in EUDAMED and any other local databases</li>



<li><strong>Acting as the liaison </strong>between the competent authorities and manufacturer</li>



<li><strong>Vigilance activities – </strong>support the manufacturer with handling vigilance reports and corrective and preventative actions</li>
</ul>



<h2 class="wp-block-heading">Unlocking Strategic Value:</h2>



<p class="wp-block-paragraph">While fulfilling these core responsibilities is essential, a forward-thinking EC-REP can offer much more. Here&#8217;s how to transform your EC-REP into a strategic partner</p>


<div class="wp-block-image">
<figure class="aligncenter size-full"><img loading="lazy" decoding="async" width="500" height="484" src="https://lumisinternational.com/wp-content/uploads/2025/02/beyond-compliance-diagram.jpg" alt="Authorized rep as a strategic partner" class="wp-image-46365"/></figure>
</div>


<div style="height:1em" aria-hidden="true" class="wp-block-spacer"></div>



<ul class="wp-block-list">
<li><strong>Regulatory Intelligence:</strong> A well-connected EC-REP shares valuable insights into the evolving regulatory landscape, including upcoming changes, interpretation of existing regulations, and market trends. They provide proactive guidance, helping you anticipate challenges and capitalize on opportunities. Ask your EC-REP about:
<ul class="wp-block-list">
<li>Upcoming regulatory changes and their potential impact on your devices.</li>
</ul>
</li>



<li><strong>Strengthen Your Supply Chain, Strengthen Your Sales:</strong> Your locally-based authorised representative can provide access to a range of distributors and importers in their network. This opens a broader supply chain, enhancing market penetration and sales.</li>



<li><strong>Post-Market Surveillance and Vigilance Support:</strong> Post-market surveillance is a crucial aspect of regulatory compliance. A proactive EC-REP assists with:
<ul class="wp-block-list">
<li>Supporting vigilance reporting and incident investigations.</li>



<li>Advising on corrective and preventative actions</li>
</ul>
</li>
</ul>



<p class="wp-block-paragraph">The authorised representative will also be a focal point for product feedback which can be used to improve product performance, safety, and customer satisfaction. &nbsp;</p>



<ul class="wp-block-list">
<li><strong>Access to a Network of Experts:</strong> Experienced EC-REPs offer broad regulatory consulting services and often have links to additional experts like legal specialists, local marketing and sales teams, contract research organisations, and others. An established authorized representative should be your strategic coordinator in Europe.</li>
</ul>



<h2 class="wp-block-heading">Choosing the Right EC-REP:</h2>



<p class="wp-block-paragraph">Selecting the right EC-REP is crucial for maximizing the strategic value of this relationship. Consider the following criteria:</p>



<ul class="wp-block-list">
<li><strong>Expertise:</strong> Look for an EC-REP with a proven track record in medical device regulations and in-depth knowledge of the MDR/IVDR. Be sure they understand their responsibilities in detail and have solid procedures in place to manage their regulatory obligations.</li>



<li><strong>Communication and Responsiveness:</strong> Choose a representative who is readily accessible, communicates clearly, and responds promptly to inquiries.</li>



<li><strong>Network and Resources:</strong> Evaluate their network of contacts and resources, including the ability to provide local support and access to specialized expertise.</li>



<li><strong>Proactive Approach:</strong> Seek an EC-REP who demonstrates a proactive approach to &nbsp;&nbsp;compliance and offers strategic guidance beyond basic requirements.</li>
</ul>



<h2 class="wp-block-heading">Conclusion:</h2>



<p class="wp-block-paragraph">By viewing your EC-REP as more than just a compliance requirement, you unlock significant strategic value. A well-networked and experienced representative provides valuable market intelligence, streamlines communication, and supports post-market surveillance, while providing access to a range of experts.</p>



<p class="wp-block-paragraph">Choosing the right authorized representative and fostering a strong partnership ensures a significant advantage for medical device companies navigating the complexities of EU regulations and achieving long-term commercial success.</p>



<h2 class="wp-block-heading">How can Lumis Help?</h2>



<p class="wp-block-paragraph">Lumis’ authorised representative service uniquely combines medical device regulatory expertise and a vast network to provide a strategically powerful advantage to our clients. We have decades of experience in medical device regulations and we specialise in representing clients in Europe.</p>



<p class="wp-block-paragraph">Lumis’ state-of-the-art procedures ensure we comply with our EC-REP legal obligations, but we also offer a range of services and work with carefully selected partners to provide an all-encompassing solution.</p>



<p class="wp-block-paragraph">If you want to bring your medical device to Europe, contact us for more information.</p>
<p>The post <a href="https://lumisinternational.com/beyond-compliance-transform-your-authorized-representative-into-a-strategic-partner/">Beyond Compliance: Transform Your Authorized Representative into a Strategic Partner</a> appeared first on <a href="https://lumisinternational.com">Lumis International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
